{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-23-021752","form_type":"8-K","ticker":"MLAB","cik":"0000724004","company_name":"MESA LABORATORIES INC /CO/","filed_at":"2023-08-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:36.509732+00:00","generated_at":"2026-06-12T09:59:49.120940+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Mesa Labs 1Q24 revenue $50.6M (+0.4%), net loss $(0.10)/share, AOI up 46% to $9.5M","bullets":["Revenue $50.6M, +0.4% YoY; core organic growth 2.0% (ex-currency/COVID).","Operating loss narrowed 85.5% to $(0.7M); net loss $(0.5M) or $(0.10)/share.","Non-GAAP AOI excluding unusual items rose 46.2% to $9.5M (18.8% of revenue).","Divisions: Calibration +12.5% core organic, Sterilization +7.2%, Clinical Genomics -4.4%, Biopharma -6.6%.","Headwinds: slowing capital equipment, Sema4 loss, currency; cost cuts aiding profitability."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-23-021752","json":"https://secwatch.observer/filing/0001437749-23-021752.json","markdown":"https://secwatch.observer/filing/0001437749-23-021752.md","text":"https://secwatch.observer/filing/0001437749-23-021752.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/724004/000143774923021752/0001437749-23-021752-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/724004/000143774923021752/mlab20230802_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T09:59:49.120940+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"5349e7012a5bb1bc300780befe32cb8f8ee3cc49","claim":"MESA LABORATORIES INC /CO/ reported the three months ended June 30, 2023 results: revenue $50,645, net income $(549), EPS $(0.10) per diluted share.","evidence_excerpt":"Total revenues were $50,645, an increase of 0.4% compared to the first quarter of fiscal year 2023 (“1Q23”) as last year’s acquisition of Belyntic made a modest contribution to revenue. Operating loss decreased 85.5% to $ (664). Net loss was $(549), a decrease of 61.8% or $(0.10) per diluted share of common stock.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/724004/000143774923021752/0001437749-23-021752-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three months ended June 30, 2023"},{"label":"Revenue","value":"$50,645"},{"label":"Net income","value":"$(549)"},{"label":"EPS","value":"$(0.10) per diluted share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}